CAMP - NASDAQ
CAMP4 Therapeutics Corporation
$4.37
+4.8%CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
At a Glance
Live Snapshotcamp
Total Liabilities
Last Annual Value
70.10M
3-Year CAGR
-27%
5-Year CAGR
-27%
10-Year CAGR
-10%
CAMP4 Therapeutics Corporation Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
CAMP4 Therapeutics Corporation NASDAQ:CAMP | 70.10M | -26.8% | -26.3% | -11.7% | |
 Unicycive Therapeutics, Inc. NASDAQ:UNCY | 18.94M | 1.7% | 53.0% | N/A | |
 Cue Biopharma, Inc. NASDAQ:CUE | 15.78M | -13.6% | -2.5% | 30.5% | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 28.89M | 14.9% | 19.4% | N/A | |
 Artiva Biotherapeutics, Inc. NASDAQ:ARTV | 20.97M | -57.2% | -39.5% | N/A | |
 Precision BioSciences, Inc. NASDAQ:DTIL | 62.17M | -23.9% | -12.4% | -4.9% | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 72.68M | 21.4% | 30.5% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 7.49M | -15.0% | -13.0% | 18.5% | |
 Sutro Biopharma, Inc. NASDAQ:STRO | 306.28M | -1.6% | 28.1% | 6.7% | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 50771.84B | 10179.8% | 1845.8% | 321.2% | |
 CEL-SCI Corporation AMEX:CVM | 14.12M | -6.6% | -6.1% | 1.2% |
CAMP4 Therapeutics Corporation Fair Value Envelope
Related Guides
Continue your CAMP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.